Criteria to qualify for study: Drug used in study:
  • Confirmed MYD88 and CXCR4 mutations

LYM 165

A Phase 1b Trial of Mavorixafor, an oral CXCR4 Antagonist, in combination with Ibrutinib in patients with Waldenstrom’s Macroglobulinemia (WM) whose tumors express mutations of MYD88 and CXCR4

Criteria to qualify for study: Drug used in study:
  • B-Cell NHL, CLL-SLL, Waldenstrom Macrogloblinemia, Richter’s transformation, Follicular Lymphoma, MCL, MZL

HR 52

A Phase 1 Dose Escalation Study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of ARQ 531 in selected subjects with Relapsed or Refractory Hematologic Malignancies.